182 related articles for article (PubMed ID: 9057584)
21. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.
Buscombe JR; Holloway B; Roche N; Bombardieri E
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):109-18. PubMed ID: 15243412
[TBL] [Abstract][Full Text] [Related]
22. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
23. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672
[TBL] [Abstract][Full Text] [Related]
24. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
[TBL] [Abstract][Full Text] [Related]
25. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
26. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
27. Nuclear imaging of bone tumors: FDG-PET.
Aoki J; Inoue T; Tomiyoshi K; Shinozaki T; Watanabe H; Takagishi K; Endo K
Semin Musculoskelet Radiol; 2001 Jun; 5(2):183-7. PubMed ID: 11500164
[TBL] [Abstract][Full Text] [Related]
28. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
[TBL] [Abstract][Full Text] [Related]
29. Imaging of bone sarcomas.
Cummings JE; Ellzey JA; Heck RK
J Natl Compr Canc Netw; 2007 Apr; 5(4):438-47. PubMed ID: 17442234
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
[TBL] [Abstract][Full Text] [Related]
31. Musculoskeletal system.
Jadvar H; Gamie S; Ramanna L; Conti PS
Semin Nucl Med; 2004 Oct; 34(4):254-61. PubMed ID: 15493003
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET/CT in pediatric solid tumors.
Franzius C
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):401-10. PubMed ID: 20823808
[TBL] [Abstract][Full Text] [Related]
33. [Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference "PET in Oncology": results of the Bone and Soft Tissue Study Group].
Franzius C; Schulte M; Hillmann A; Winkelmann W; Jürgens H; Bockisch A; Schober O
Chirurg; 2001 Sep; 72(9):1071-7. PubMed ID: 11594280
[TBL] [Abstract][Full Text] [Related]
34. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
35. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma.
Buchbender C; Heusner TA; Lauenstein TC; Bockisch A; Antoch G
J Nucl Med; 2012 Aug; 53(8):1244-52. PubMed ID: 22782313
[TBL] [Abstract][Full Text] [Related]
36. Soft Tissue Special Issue: Imaging of Bone and Soft Tissue Sarcomas in the Head and Neck.
Tran NA; Guenette JP; Jagannathan J
Head Neck Pathol; 2020 Mar; 14(1):132-143. PubMed ID: 31950470
[TBL] [Abstract][Full Text] [Related]
37. Technetium-99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma.
Karanikas G; Köstler WJ; Becherer A; Wiesner K; Dudczak R; Krainer M; Kletter K
Oncol Rep; 2002; 9(5):1009-13. PubMed ID: 12168065
[TBL] [Abstract][Full Text] [Related]
38. Review of non-positron emission tomography functional imaging of primary musculoskeletal tumours: beyond the humble bone scan.
Ho YY
Australas Radiol; 2005 Dec; 49(6):445-59. PubMed ID: 16351608
[TBL] [Abstract][Full Text] [Related]
39. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity.
Jager PL; Plaat BE; de Vries EG; Molenaar WM; Vaalburg W; Piers DA; Hoekstra HJ
Clin Cancer Res; 2000 Jun; 6(6):2252-9. PubMed ID: 10873075
[TBL] [Abstract][Full Text] [Related]
40. [(11)C]methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy.
Zhang H; Yoshikawa K; Tamura K; Tomemori T; Sagou K; Tian M; Kandatsu S; Kamada T; Tsuji H; Suhara T; Suzuki K; Tanada S; Tsujii H
Clin Cancer Res; 2004 Mar; 10(5):1764-72. PubMed ID: 15014030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]